New drug shrinks skin cancer before surgery in early trial
NCT ID NCT04154943
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 24 times
Summary
This study tested a drug called cemiplimab given before surgery to people with stage II to IV cutaneous squamous cell carcinoma (a type of skin cancer). The goal was to see if the drug could eliminate or shrink the tumor before surgery. 79 participants received the treatment, and researchers measured how many had a complete response (no cancer left in the removed tissue). The study also looked at safety and whether the drug changed the surgical plan.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Regeneron Study Site
Palo Alto, California, 94304, United States
-
Regeneron Study Site
Washington D.C., District of Columbia, 20037, United States
-
Regeneron Study Site
Miami, Florida, 33176, United States
-
Regeneron Study Site
Tampa, Florida, 33612, United States
-
Regeneron Study Site
Baltimore, Maryland, 21231, United States
-
Regeneron Study Site
Boston, Massachusetts, 02114, United States
-
Regeneron Study Site
Boston, Massachusetts, 02215, United States
-
Regeneron Study Site
Ann Arbor, Michigan, 48109, United States
-
Regeneron Study Site
Omaha, Nebraska, 68114, United States
-
Regeneron Study Site
New York, New York, 10065, United States
-
Regeneron Study Site
Charlotte, North Carolina, 28204, United States
-
Regeneron Study Site
Durham, North Carolina, 27710, United States
-
Regeneron Study Site
Cleveland, Ohio, 44195, United States
-
Regeneron Study Site
Dallas, Texas, 75390, United States
-
Regeneron Study Site
Houston, Texas, 77030, United States
-
Regeneron Study Site
St Leonards, New South Wales, 2065, Australia
-
Regeneron Study Site
Herston, Queensland, 4029, Australia
-
Regeneron Study Site
Melbourne, Victoria, 3000, Australia
-
Regeneron Study Site
Dresden, 01307, Germany
-
Regeneron Study Site
Essen, 45147, Germany
-
Regeneron Study Site
Kiel, 24105, Germany
-
Regeneron Study Site
Tübingen, 72076, Germany
Conditions
Explore the condition pages connected to this study.